Literature DB >> 11059082

Hypnotics. Options to help your patients stop.

M Woodward1.   

Abstract

BACKGROUND: There are a wide range of reasons why hypnotic agents may be started, but there is substantive evidence that they are often overused or misused.
OBJECTIVE: To review the reasons for stopping hypnotic agents, how to detect their use, how to facilitate the decision to withdraw and how to most effectively achieve withdrawal. In this article, the target group is using but not intentionally abusing hypnotic agents. DISCUSSION: In many cases it is possible for patients to permanently stop using hypnotic drugs. Withdrawal can generally be achieved in the community, using a gradual taper regimen, although it is often a difficult process and is more effective when the patient is aware of the health benefits to be gained from withdrawal. Once withdrawn, other approaches to maintain sleep need to be reinforced to reduce the risk of recommencing hypnotic therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11059082

Source DB:  PubMed          Journal:  Aust Fam Physician        ISSN: 0300-8495


  4 in total

1.  Psychotropic drug use among older people in general practice: discrepancies between opinion and practice.

Authors:  Andrea Lasserre; Nadia Younès; Thierry Blanchon; Inge Cantegreil-Kallen; Christine Passerieux; Guy Thomas; Christine Chan-Chee; Thomas Hanslik
Journal:  Br J Gen Pract       Date:  2010-04       Impact factor: 5.386

Review 2.  A composite screening tool for medication reviews of outpatients: general issues with specific examples.

Authors:  Peter A G M De Smet; Wilma Denneboom; Cees Kramers; Richard Grol
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

3.  Clinical implications of changes in hepatic drug metabolism in older people.

Authors:  Sarah N Hilmer; Gillian M Shenfield; David G Le Couteur
Journal:  Ther Clin Risk Manag       Date:  2005-06       Impact factor: 2.423

Review 4.  Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping review.

Authors:  André S Pollmann; Andrea L Murphy; Joel C Bergman; David M Gardner
Journal:  BMC Pharmacol Toxicol       Date:  2015-07-04       Impact factor: 2.483

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.